Oncology Central’s Post

Welcome to Trivia Week, where each day brings you a new challenge to test your knowledge and raise awareness about prostate cancer as we prepare for Prostate Cancer Awareness Month. Day 1 is officially here! How well did you do with today’s trivia? If you got it right, give yourself 5 points! Comment on your total points earned below throughout the week. Read more facts here: https://lnkd.in/eHHciwe2.   #TriviaWeek #ProstateCancerAwareness

𝘿𝙤 𝙮𝙤𝙪 𝙝𝙖𝙫𝙚 𝙖𝙣𝙮 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙬𝙝𝙤 𝙬𝙤𝙪𝙡𝙙 𝙡𝙞𝙠𝙚 𝙩𝙤 𝙡𝙚𝙖𝙧𝙣 𝙢𝙤𝙧𝙚 𝙖𝙗𝙤𝙪𝙩 𝙥𝙧𝙤𝙨𝙩𝙖𝙩𝙚 𝙘𝙖𝙣𝙘𝙚𝙧 𝙩𝙝𝙚𝙧𝙖𝙣𝙤𝙨𝙩𝙞𝙘𝙨? This consumer session with leading medical experts will answer all their questions about the emerging field of theranostics, which has provided an entirely new way to treat metastatic prostate cancer. This session is part of the ProsTIC Theranostics Preceptorship - a conference bringing together experts from across the globe. To register: https://lnkd.in/gebCNe5Z

About 7-Methoxyflavone 7-Methoxyflavone impedes the development of breast cancer and could be used as a chemoprevention agent. It may also boost testosterone levels. Know more about #7Methoxyflavone click the link below 👇 https://lnkd.in/gczu8ud6

FAQ Friday! Each Friday we post a Frequently Asked Question about lobular breast cancer from our website on social media. The answers to these questions were developed with the input of LBCA scientific advisory board members. This week's question is "What are the different subtypes of (ILC)?" View the answer on our website FAQ Section I Question #3 here: https://lnkd.in/eSzUPuMH #LobularBreastCancer #ILCFAQ

To wrap up the prostate cancer series at #ESMO24, Dr. Eleni Efstathiou and colleagues share insights on everything from ARANOTE to Contact-02 in the final roundtable coverage. https://lnkd.in/eHx237r5

#BreastCancerAwarenessMonth – A CCTG trial spotlight: MAC27 is a breast clinical trial with the goal of finding out if the combination of a new drug and a commonly used drug is better than the commonly used drug alone at preventing this type of breast cancer from returning. #SolvingCancerTogether #ClinicalTrials https://buff.ly/3U2gbP5

🎥 Latest From SGO & ESGO: DUO-E Trial Highlights 🔍 Join Prof Jean-Francois Baurain as he presents critical data from the DUO-E trial at SGO and ESGO, exploring first-line treatment options for endometrial cancer. Learn about the impact of checkpoint inhibitors and the potential enhancements from combining durvalumab with chemotherapy and olaparib. Discover these updates.👇 For all ESGO & SGO 2024 videos, find the link in the comments! #MediMix #ESGO2024 #SGO2024 #EndometrialCancer #CancerResearch

On World Cancer Day, remember that early detection is essential when it comes to Breast Cancer. Empower yourself & those you love by learning a life-saving skill - Apne Liye. Apno Ke Liye. To learn more about Project Hug of Life, visit https://lnkd.in/d3bqUGsm #SBILife #ApneliyeApnokeliye #WorldCancerDay

WATCH: Following ASCO GU 2024, a panel of GU medical oncologists discuss recent updates in bladder cancer and provide comprehensive insights on the evolving treatment landscape. #GU24 #oncology https://lnkd.in/eHmfnAwi

The data from 27,010 participants, 45-85YO, showed PREEMPT blood-based CRC test had sensitivity 80.5%, specificity 91.5% for non-advanced colorectal neoplasia at CMS’s NCD recommended cutoff of 90%. 12.5% sens for advanced adenomas, and 29% sens for Stage 0. When powered at 96%+, sens 79.2%, spec 91.5%. Stage I: 57.1%, II: 100%, III: 82.4%, IV: 100%. Important part: Freenome has already collected study data to improve the test. The sample size can be increased by >59%.